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Abstract
Dupuytren’s disease (DD) is a benign, fibroproliferative disease of the palmar fascia, with excessive extracellular matrix (ECM)
deposition and over-production of cytokines and growth factors, resulting in digital fixed flexion contractures limiting hand
function and patient quality of life. Surgical fasciectomy is the gold standard treatment but is invasive and has associated
morbidity without limiting disease recurrence. Injectable Collagenase Clostridium histolyticum (CCH) - XiaflexH - is a novel,
nonsurgical option with clinically proven in vivo reduction of DD contractures but with limited in vitro data demonstrating
its cellular and molecular effects. The aim of this study was to delineate the effects of CCH on primary fibroblasts isolated
from DD and non-DD anatomical sites (using RTCA, LDH, WST-1, FACS, qRT-PCR, ELISA and In-Cell Quantitative Western
Blotting) to compare the efficacy of varying concentrations of XiaflexH against a reagent grade Collagenase, Collagenase A.
Results demonstrated that DD nodule and cord fibroblasts had greater proliferation than those from fat and skin. XiaflexH
exposure resulted in dose- and time-dependent inhibition of cellular spreading, attachment and proliferation, with cellular
recovery after enzyme removal. Unlike Collagenase A, XiaflexH did not cause apoptosis. Collagen expression patterns were
significantly (p,0.05) different in DD fibroblasts across anatomical sites - the highest levels of collagen I and III were
detected in DD nodule, with DD cord and fat fibroblasts demonstrating a smaller increase in both collagen expression
relative to DD skin. XiaflexH significantly (p,0.05) down-regulated ECM components, cytokines and growth factors in a
dose-dependent manner. An in vitro scratch wound assay model demonstrated that, at low concentrations, XiaflexH
enabled a faster fibroblast reparatory migration into the wound, whereas, at high concentrations, this process was
significantly (p,0.05) inhibited. This is the first report elucidating potential mechanisms of action of XiaflexH on Dupuytren
fibroblasts, offering a greater insight and a better understanding of its effect in DD.
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Introduction
Dupuytren’s Disease (DD) is a common, benign, fibroproliferative
disorder affecting the palmar fascia of the hands, resulting in
progressively disabling fixed flexion deformities of the digits [1–4]. It
is of controversial aetiology [5], and the reported associations
identified to date are of varying significance including genetic
inheritance [6,7], smoking [8], diabetes mellitus [9,10], alcohol
consumption [11], hyperlipidaemia [12], anti-epileptic medications
[13], localised trauma [14] and occupational vibration exposure [15].
DD is primarily a disease affecting older Caucasian males of
Northern European descent, with a male to female ratio of
between 5:1 and 15:1 [16]. The classical presentation of DD is
from the fifth decade onwards [2] with a markedly higher
prevalence within the British, North American, Scandinavian and
Australasian populations [17]. The complex aetiological picture is
mirrored by the incomplete multi-factorial pathophysiological
model - DD manifests with a tripartite natural history of
myofibroblast proliferation (resulting in nodule formation),
cytokine- and mechanically-triggered actin microfilament contrac-
tion coupled with extracellular matrix (ECM) remodelling (with
ensuing development of shortening fascial bands) and nodule
regression, leaving the inelastic, tendon-like cords which result in
the classically-described digital flexion contractures [2,18–21].
Treatment of DD is not curative but rather aims to restore hand
function. Currently, the gold standard remains surgical correction
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31430of the deformity but a variety of non-surgical treatments have been
investigated. To date, the use of Collagenase Clostridium
Histolyticum (CCH) has shown the most promise [22,23]. The
CCH family, first discovered by Maclennon in 1953, comprises a
group of matrix metalloproteases that digest the triple-helical
structure of collagen under physiological conditions. They have
had an extensive history of laboratory utilisation but are becoming
increasingly of interest in the therapeutic management of a variety
of fibrotic disorders, to date most successfully in the amelioration
of palpable DD cords [22–24]. They contain both class I and class
II collagenolytic enzymes, which act to rapidly digest triple-helical
collagens into small peptides [25,26]. A variety of reagent grade
collagenases have been available on the market however, while
useful in the laboratory, these have not had a fixed ratio of class I
to class II component-CCHs, leading to difficulties with achieving
a reproducible therapeutic in vivo effect. XiaflexH solves this issue
with a constant I:II (AUX-I:AUX-II) collagenase class ratio (each
of which is a product of a separate bacterial gene, colG and colH
respectively) [27], which is thought to increase its targeted
effectiveness and reliability via the synergistic activity of its
contained collagenases. The class I collagenase is a single
polypeptide chain containing approximately 1000 amino acids of
known sequence and with a molecular weight of 114 kDa. The
class II collagenase is also approximately 1000 amino acids long
and has a molecular weight of 113 kDa. Respectively, these
enzymes differ from each other in terms of domain structure,
substrate affinity, catalytic efficiency and preferred cleavage site on
the collagen molecule [22,23,28–33]. In vivo results (phase 1–3
clinical trials [31–35] and the successful achievement of FDA
approval [36]) have shown good therapeutic short- to mid-term
effects in the non-operative amelioration of palpable DD cord
contractures [22], although recurrence rates have been shown to
be higher than those observed following surgical excision of the
diseased tissues. Interestingly, to date, there have been no in vitro
studies published demonstrating the effect of XiaflexH at the
cellular or molecular level.
CCHs act on collagen, the major structural component of
connective tissues and perhaps the most abundant protein in the
animal world. Twenty-eight types of collagen have been described
and have been grouped based on structure and function into eight
distinct classes – however, the major human structural forms are
the fibrillar collagens types I, II and III. Each consists of three
triple helical polypeptide al-chains: type I collagen = al (I), al (I),
a2 and type III collagen = al (III), al (III), al (III) [37,38,39,40]. It
is unclear which local factors govern the abnormal DD ratio of
type III to type I collagen in DD cord tissue compared to normal
palmar fascia. An increase in both total collagen in DD tissue and
in the ratio of type III to type I collagen has been consistently
demonstrated [19,41]. Additionally, the collagen produced has a
higher degree of post-translational modification (hydroxylation
and/or glycation of lysine and proline side chains) than is found in
normal palmar fascia [19,41]. The over-expression of type III to
type I collagen becomes more apparent in DD progression from
normal (control) palmar fascia through to mildly involved fascia
and to DD nodules, but type III prevalence decreases in the
evolution from nodules to DD cords [19].
Morphologically, the major difference between normal and DD
palmar fascia is a 4- to 20-fold increase in DD fascia fibroblast
density [42,43]. Collectively, these changes indicate that DD
represents a localised increase in collagen turnover and remod-
eling, a process analogous to that which occurs during physiolog-
ical wound healing [18–20].
The effects of collagenase on the collagenous components of
DD cords (with morphologic sparing of cellular elements) [44] has
been well described in in vitro explant cultures [33,44]. However,
there has been little published to date regarding the functional
effects of CCH on DD tissue at a cellular level. The aim of this
study was to investigate, using in vitro assays, the functional effects
of XiaflexH and Collagenase A on fibroblasts cultured from DD
Nodule, DD Cord, surrounding perinodular Fat and overlying
Skin which were compared to control fascial, skin and fat
fibroblasts (from carpal tunnel release patients), focusing on
fibroblast adhesion, proliferation, apoptosis, migration and gene
expression.
Materials and Methods
Participant Selection
This study was conducted in accordance with the ethical
principles of Good Clinical Practice and the Declaration of
Helsinki. This study received ethical approval from the local
research committee (Manchester, UK) and all subjects gave full
written, informed consent.
Participants were drawn from a cohort of day-case procedures
performed at University Hospital South Manchester NHS
Foundation Trust and Salford Royal NHS Foundation Trust,
Manchester, UK. Patients with DD requiring fasciectomy or
dermofasciectomy and those undergoing carpal tunnel release
(screened prior to selection to ensure they were DD-free based on
history, lack of family history of DD and clinical examination)
were recruited to provide the study subjects respectively. Table 1
demonstrates DD (n=25) and CT (n=6) patient demographics
and relevant DD risk factor exposure. Control subjects with
history of fibrosis and/or family history of DD were excluded.
Sampling procedure
In the DD cases (n=25), the palmar and digital DD-affected
tissues were therapeutically excised. Tissues from the Nodule,
Cord, peri-nodular Fat and surrounding Skin were carefully
dissected, separated and immediately placed aseptically into
complete Dulbecco’s Modified Eagle Medium (cDMEM) (Sig-
ma-Aldrich, UK) – this contained Dulbecco’s Modified Eagle
Medium (DMEM) plus 1 mL Primocin (InvivoGen, UK), 5 mL
non-essential amino acids (Sigma-Aldrich, UK), 5 mL L-gluta-
mine (PAA, UK) and 50 mL (10%) fetal bovine serum (FBS)
(PAA, UK) per 500 mL of DMEM. Control Skin, palmar Fascia
and Fat were harvested from subjects undergoing carpal tunnel
release (n=6). Control tissue was carefully excised and again
placed aseptically into cDMEM. All samples were refrigerated at
4uC. The tissue samples were processed within 12–16 hours
subsequent to tissue harvest during the surgical procedure
(Figure 1).
Table 1. Demographic data of DD and control subjects.
Characteristics
Patients with
Dupuytren’s
Disease
Controls subjects
undergoing Carpal
Tunnel Release
Total number 25 6
Gender (Male/Female) 20/5 4/2
Race or Ethnicity Caucasian Caucasian
Age, Year, Mean 66.3 70
Age range (Year) 39–80 41–70
Positive family history (%) 13 (52) 0 (0)
doi:10.1371/journal.pone.0031430.t001
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Each tissue type was processed using previously described cell
culture techniques [45] to allow growth of each tissue component
i.e. Cord, Nodule, Fat, non-diseased Fascia and Skin. Tissue
handling and cell culture experiments were undertaken within a
class 2 biological containment extractor hood to limit bacterial or
fungal contamination. Briefly, each sample was washed with PBS
(Sigma-Aldrich, UK) prior to being minced with a small quantity
of Collagenase A (10 mg/mL, Roche, UK) and incubated for 2–
3 hours in a 37uC water bath, with a sufficient volume of
Collagenase A to lyse the tissue. The tissue lysis reaction was
arrested using equal amounts of cDMEM and the resultant cell
suspension was centrifuged. The supernatant was removed and the
cell pellet was re-suspended in 1 mL cDMEM, this was then
added to a T-25 Corning CellBind flask (Corning Life Sciences,
UK). A further 4 mL cDMEM was added and the flask was
incubated in a 5% CO2 humidified incubator at 37uC for 1–2
weeks to achieve 80–85% cell confluency. At 85% confluency, this
was denoted as passage 0, the cells were passaged for experimental
usage (with a small percentage re-seeded into the flasks as passage
1). Passages 0–4 were utilised, following which the cells were
destroyed. Throughout the growth period, each flask had the old
media removed every 3-4 days, was washed with PBS to remove
debris and fresh cDMEM was added. Prior to use in any
experiments, the 85% confluent flasks were serum-starved by
incubating overnight with 0.1% FBS in DMEM to ensure all cells
were synchronized within the G0 cell-cycle (cell synchrony is
required to study the progression of cells through the cell cycle
prior to subjecting them to any drug treatment). Following this, the
cells were trypsinised into suspension, counted using a haemocy-
Figure 1. Flowchart demonstrating the tissue collection, processing and experimental strategy used in this study.
doi:10.1371/journal.pone.0031430.g001
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4 cells were
calculated for each sample.
XiaflexH versus Collagenase A
The relative and dose-dependent effects of XiaflexH (Auxilium
Pharmaceuticals, USA) and a commercially available reagent
grade collagenase, Collagenase A (Roche Diagnostics, UK), on
DD and CT primary cultured fibroblasts from each anatomical
site were assessed. The following enzyme concentrations were
compared: No XiaflexH or Collagenase A (untreated); Collagenase
A 250, 750 and 1000 ng/mL (designated as Col-250 ng; Col-
750 ng and Col-1000 ng); XiaflexH 300, 400, 500, 600, 700 ng/
mL (designated as Xia-300 ng; Xia-400 ng; Xia-500 ng; Xia-
600 ng and Xia-700 ng). Camptothecin 250 ng/mL was used as a
positive control for RTCA, LDH, WST-1 and apoptotic endpoint
assays (Figure 1) due to its well-documented inhibitory effect on
growth and proliferation and its positive apoptotic effect.
Composition of serum free supplemented media for the
study and for drug dilution
A variety of media were evaluated in the pre-study methodolog-
ical pilots. Two were found to provide the best environment for cell
growth and maintenance while not affecting the action of either
enzyme. These were serum-free Dulbecco’s Modified Eagle’s
Medium/Ham’s F12 (50:50) (supplemented with 10 mM HEPES,
50 mg/mL ascorbic acid, 100 mM adenine, 0.5 mM hydrocortisone,
0.1 nM cholera toxin, 100 U/mL penicillin and 10 g/mL strepto-
mycin (Sigma-Aldrich, UK) (known hereafter as supDMEM) [46]
and William’s E medium (supplemented with 10 mg/mL of insulin,
10 ng/mL of hydrocortisone, 2 mmol/L of l-glutamine, 100 IU/
mL penicillin and 10 g/mL streptomycin (Sigma-Aldrich, UK)
(referred to hereafter as supWillE) [47]. For all the experiments, the
enzymes were diluted in these media and their effect compared.
Real-Time Cellular Analysis (RTCA)
The xCELLigence System (Roche Applied Science, Germany
and ACEA Biosciences USA) allows real time cell analysis (RTCA)
via a system consisting of a microelectronic sensory array (MESA)
96 well plate coupled with a device station and an electronic sensor
analyser. The basic principle of the RTCA system is to monitor
the changes in electrode impedance by the interaction between
adherent multiplying cells seeded into the MESA wells and the
underlying well microelectrodes. The ionic environment, both at
the electrode/solution interface and in the surrounding solution,
determines the electronic impedance of each electrode. When an
electric field is applied, ions undergo field-directed movement
coupled with concentration gradient-driven diffusion, leading to
frequency-dependent impedance dispersion. The cell number,
viability, morphology and degree of adherence of cells in contact
with the electrodes will affect the local ionic environment leading
to an increase in the electrode impedance - this is represented as
the Cell Index (CI) and reflects a calculation (via an internal
system algorithm) of frequency-dependent electrode impedance
with or without attached healthy cells present on the surface of the
wells (Supplementary Figure S1) [48,49].
For each experiment, a MESA plate was prepared with 50 mlo f
either supDMEM or supWillE added to each well and the plate re-
incubated for temperature equilibration and plate calibration.
Defined volumes of passaged cell suspensions containing 1.5610
4
cells were added to each well. The plate was then inserted into the
RTCA machine (housed within the incubator) and CI values
assessed every 15 min over the following 7–8 hours (allowing cell
attachment, spreading and growth).
After 7–8 hours the plate was removed, washed once with PBS
(Sigma-Aldrich, UK) to remove any cell debris and either XiaflexH
or Collagenase A (at varying concentrations as described above)
was added to each well. The plate was reinserted into the RTCA
system and the CI further assessed every 15 min for the next
24 hours. Following this 24 hour period, the medium containing
the enzymes was removed, the wells were again washed once with
PBS and fresh supDMEM or supWillE added to all wells. The
plate was then reinserted into the RTCA system for a minimum of
a further 24–30 hours to assess the degree of cellular recovery in
the absence of XiaflexH or Collagenase A.
Cytotoxicity, Cell Death and Cell Viability/Metabolic
Activity Assay (LDH/WST-1)
Synchronized cells were passaged for cell suspensions and
plated, with 1.5610
4 cells per well, onto a 96 well plate. The cells
were grown for 7–8 hours, after which XiaflexH or Collagenase A
(at the concentrations described above) were applied and the cells
grown for 24 hours in the presence of either enzyme. Treated cells
and media were then collected, following which lactate dehydro-
genase (LDH) and water soluble tetrazolium salt-1 (WST-1
[containing 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,
3-benzene disulfonate]) assays were performed to assess cell
membrane integrity, cellular viability and cell metabolic activity,
using the standard protocol as described by the manufacturer’s
instructions (Roche, UK). The remaining treated cells were allowed
to grow further following the removal of the enzymes, with fresh
enzyme-free media applied to study the reversibility of the enzyme
effects. The remaining media and cells were then collected after 24–
30 hours of further cell growth, following which LDH and WST-1
assays were performed.
RNA Extraction, cDNA synthesis and qRT-PCR
1.5610
4 cells from different anatomical sites, following exposure
to the various CCH enzymes (at the concentrations previously
noted), were collected in 300 ml of Trizol (Invitrogen, UK), mixed
well with 0.2 mL chloroform and left at room temperature for
2 min. The mixture was then spun at 13,000 rpm for 15 min. The
upper aqueous layer was collected in RNA-free eppendorf tubes
and mixed with an equal volume of 70% ethanol, then further
processed with an RNeasy kit (Qiagen, UK) to extract total RNA
(as per the manufacturer’s instructions). DNase treatment was then
carried out using a DNAfree kit (Ambion, UK) as per the
manufacturer’s protocol. The NanoDrop ND-1000 UV-visible
spectrophotometer (Labtech International, UK) was then used to
estimate the total RNA concentration. RNA was normalised for all
the cells samples to 500 ng for the cDNA synthesis. qScript
TM
cDNA SuperMix (Quanta Biosciences, USA) was used for cDNA
synthesis. Quantitative polymerase chain reactions were carried
out in real-time using the LightCyclerH480 II platform (Roche,
UK). Each qRT-PCR reaction was carried out in a final volume of
10 ı `L, consisting of 4 ı `L diluted template cDNA, 5 ı `L Light Cycler
480 probes master mix (Roche Diagnostics, UK), 0.2 ı `M of
forward and reverse primer (Supplementary Table S1) (Sigma-
Aldrich, UK), 1 ı `L probe from Universal Probe Library (Roche
Diagnostics, UK) and 0.5 ı `L nuclease-free water (Ambion, UK).
Each reaction was done in triplicate. White 96-well plates (Roche
Diagnostics, UK) were used for all the experiments. The
quantitative real-time polymerase chain reaction (qRT-PCR)
reactions were initiated at 95uC for 10 minutes to activate the
Hot Start Taq polymerase. Each of the 40 amplification cycles
consisted of a 10-second denaturation step at 95uC and a 30-
second annealing and elongation step at 60uC. The fluorescence
intensity was recorded at the end of the annealing step and
XiaflexH Effect on DD Fibroblasts
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using MESA. Primary fibroblasts of DD (Nodule, Cord, Fat and Skin) were seeded onto the E-plate and cells were allowed to grow prior to the
introduction of XiaflexH and Collagenase A at various concentrations. After drug addition, cells were allowed to grow for 24 hours in the presence of
drugs. After 24 hrs, the drugs were removed and the cells were fed with fresh supWillE media for 24 hrs to assess the reversibility of the inhibitory
effect of the drugs. Cell Indexes were recorded every 15 minutes. Each trace at each concentration was an average of three replicates. A. Effect of
XiaflexH and Collagenase A on DD-Nodule. B. Effect of XiaflexH and Collagenase A on DD-Cord.
doi:10.1371/journal.pone.0031430.g002
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a cooling step at 40uC for 30 seconds was carried out. The gene
expression levels were normalised with an average of two internal
reference genes, ribosomal protein L32 (RPL32) and succinate
dehydrogenase complex subunit A (SDHA) [50].
Enzyme Linked Immunosorbent Assay (ELISA) for
Collagen I and III Detection
DD fibroblasts from different anatomical sites were grown in
cDMEM to 80–85% confluency, following which 1.5610
4 cells
were plated onto 96 well plates. After 7–8 hours cell attachment,
the various concentrations of XiaflexH and Collagenase A were
applied for 24 hours. Treated and control untreated cells were
collected in PBS and stored at 280uC until utilised. Collagen I was
measured using a novel capture sandwich ELISA (developed in-
house) and collagen III was measured using indirect ELISA
(standardised in-house) as described previously [50,51].
High Throughput In-Cell Western Blotting and Quantitation
80–85% confluent DD and CT cells were starved in 0.1%
serum DMEM for 24 hours, then trypsinised and counted using
FACS (Accuri C6 Flow Cytometry System, UK), with 1.5610
4
cells inoculated into each well of a 96 well plate. The cells were
grown to confluence over 8 hours, washed with PBS, the
previously described enzyme concentrations were then applied
and the plates re-incubated for 24 hours. After 24 hours
treatment, the cells were washed once with PBS, then fixed using
4% formaldehyde for 1 hour at room temperature. Following
adequate fixation, In-Cell Western blotting was carried out as
described previously [50,52–54]. Beta-actin was used as a loading
control. The panels of primary and secondary antibodies used in
this study are listed in the supplementary Tables S2 and S3.
Measurement of Early Apoptosis by Annexin V Staining
Suspensions of 1.5610
4 cells/well of DD or CT fibroblasts were
seeded as previously described onto 6-well tissue culture plates
(Corning,UK).Cellsweregrownfor7–8 hours,followingwhichthe
same concentrations of XiaflexH and Collagenase A were applied.
An AnnexinV-fluorescein isothiocyanate (AnnexinV-FITC) and
propidium iodide (PI) labelled Apoptosis/Necrosis Detection Kit
(Abcam, UK) was utilised according to the manufacturer’s
instructions. After 24 hours treatment, the cells were harvested
and AnnexinV-FITC was added to a final concentration of 2.5 mg/
ml.To detectnecrotic cellsPIwasadded at5 mg/mlconcentration.
The AnnexinV-FITC and PI-labelled cells were analysed by FACS
(Accuri C6, Flow Cytometry System, UK). Using flow cytometry,
dot plots of AnnexinV-FITC on the X-axis against PI on the Y-axis
were used to distinguish viable cells (which are negative for both PI
and AnnexinV-FITC), early apoptotic cells (which are Annexin V
positive cells, but PI negative) and late apoptotic or necrotic cells
(which are positive for both PI and AnnexinV-FITC staining). Non-
stained cells and untreated cells were used as negative controls. The
resultant data was analysed using CFlow plus software (Accuri C6,
Flow Cytometry System, UK).
In Vitro Scratch Wound Healing Assay
DD fibroblasts were seeded uniformly (5610
4 cells/well) onto 6-
well plates and grown to 100% confluency. A wound scratch was
made across the centre of each well using a sterile 200 mL pipette
tip and any non-adherent cells were washed off. The previously
described concentrations of either XiaflexH or Collagenase A were
then added and the plates incubated for 24 hours. Cellular fixation
was achieved using 4% formaldehyde/PBS (Sigma-Aldrich, UK)
applied for 30 mins at room temperature, following which the cells
were made permeable with PBS/0.1% Triton X-100 solution
(Sigma-Aldrich, UK). The cells were then stained with Rhodamine
phalloidin-TRITC (tetramethyl-rhodamine isothiocyanate) (Sig-
ma-Aldrich, UK) - this stains the F-actin red, showing any actin
stress fibres within the cells - and 49,6-diamidino-2-phenylindole
(DAPI) (Sigma-Aldrich, UK) – this binds to DNA which
preferentially stains the nucleic double-stranded DNA fluorescent
blue, showing the cellular nuclei. For each stained well, four
micrographs were taken at 40X magnification from four different
areas using inverted Olympus IX71 microscopy (Olympus, UK)
and the number of cells that had migrated to the wound area were
counted and plotted graphically.
Figure 3. Real-Time Cell Analaysis (RTCA) monitoring of XiaflexH and Collagenase A effects on DD-primary fibroblasts obtained
from different anatomical sites. This diagram demonstrates average cell indeces (CI) of untreated and treated cell groups taken from six
independent RTCA experiments, which have been plotted.
doi:10.1371/journal.pone.0031430.g003
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Each experiment was performed independently a minimum of 3
and up to 6 times to ensure reproducibility. Data were expressed
as mean 6 SEM. Statistical evaluation of the continuous data was
performed by one-way analysis of variance, followed by Dunnett’s
t-test for between-group comparisons. Statistical analyses were
performed using the SPSS 13.0 software program (SPSS Inc.,
Chicago, IL, USA). All differences with p,0.05 were considered
statistically significant. One representative data set from each of
the 3–6 independent experiments or an average data set of all 3–6
experiments is presented where appropriate (error bars represent
SEM).
Results
Dose- and Time-Dependent Inhibition of Cell
Attachment, Spreading and Proliferation by XiaflexH and
Collagenase A
A pilot experiment assessing the validity of the methodology
demonstrated that the method required optimisation, therefore a
number of experiments were undertaken to establish the most
appropriate media for use as a diluent and the optimum cell
seeding density. The first pilot assessed the effect of XiaflexH or
Collagenase A diluted in cDMEM (i.e. with 10% FBS additive) to
the desired concentrations (as described in the methods section).
As expected, the presence of 10% FBS inhibited the action of both
XiaflexH and Collagenase A, with neither demonstrating an effect
at any tested concentration on DD nodule (Supplementary S2A)
and DD cord (Supplementary Figure S2B). In light of this, the
concentration of FBS added to the DMEM media was varied (to
1%, 2% and 5%) and the effect of this on cell growth and on the
action of both enzymes assessed. At the lower percentage FBS
concentrations, there were insufficient nutrients to support
adequate cell adhesion and growth (as demonstrated by much
lower cell index (CI) plots) and at the higher FBS concentrations,
the action of both enzymes was inhibited (data not shown).
Following this, a trial of FBS-free supplemented DMEM
(supDMEM) or supplemented William’s E (supWillE) media as
the enzyme vehicle was undertaken. As in the earlier experiments,
the FBS-free supDMEM with the varying concentrations of the
enzymes did not provide sufficient nutrients for cell growth and
thus it could not be used to determine the effect of either XiaflexH
or Collagenase A on cell viability. However, those cells exposed to
the enzymes diluted in supWillE media showed much higher CI
values compared with supDMEM, allowing satisfactory compar-
ison of the effects of both enzymes (see Supplementary Figure S3).
For this reason, all subsequent experiments utilised supWillE
medium alone. Having determined the optimal culture medium to
support both, cell growth and enzyme activity, the next pilot
investigated the optimal density of cells seeded into each MESA
plate well. Fibroblast suspension densities of 0.5610
4,1 610
4,
1.5610
4 and 2610
4cells/well were assessed, with 1.5610
4cells/
well demonstrating the best total CI and CI increase (i.e. the
highest overall monolayer density and greatest cell proliferation
over the experimental period) (data not shown). The pilot results
showed the variable effect of Collagenases at different cell densities
- at higher densities (2610
4–2.5610
4cells/well) of cells, the effects
of both XiaflexH and Collagenase A were reduced as compared to
those noted with lower cell densities (1–1.5610
4 cells/well in a
96well plate) (data not shown).
Baseline cell attachment, spreading and proliferation charac-
teristics (in the absence and presence of either XiaflexH or
Collagenase A) were evaluated by RTCA for fibroblasts isolated
from the various tissue types (see Figure 2, Figure 3 and
Supplementary Figures S4A & S4B for DD and Supplementary
Figures S5 A–C and Figure S6 for CT). Prior to treatment with the
drugs, there were obvious differences in the attachment, spreading
and proliferation rates of the cell types: in DD, Nodule and Cord
showed higher growth than Fat and Skin (as shown by cell
indexes (CI) – Nodule=4.160.5 and Cord=4.1560.4 versus
Fat=3.160.4 and Skin=3.7560.6 respectively); comparatively,
in CT, Fat and Skin showed better growth than Fascia (CI of
Fat=5.1560.1 Skin=4.2560.2 and Fascia=1.2560.3 respec-
tively). The greater cell attachment, spreading and proliferation of
Nodule and Cord compared with normal Fascia is in keeping with
the pathophysiology of this fibroproliferative disease.
Treatment with both XiaflexH and Collagenase A, caused an
overall suppression of cell attachment, spreading and proliferation
across all cell types. In DD cells, there was a marked dose-
dependent suppression (with a slight anomaly in the suppressive
effect of 500 ng XiaflexH on Fat), with XiaflexH seen to be more
effective at a low concentration (Xia-300 ng) compared with a
low-dose Collagenase A (Col-250 ng). XiaflexH appears to have a
greater effect on Nodule compared to Cord cultures - this may tie
in with the known pathophysiology of the nodules being the active
proliferative disease phase or may be related to higher myofibro-
blast numbers in nodules compared with other DD anatomical
sites. Conversely, and as expected, Camptothecin suppressed all
cell types equally. In the control CT cells, again overall, there was
a marked suppression of all cell type attachment, spreading and
proliferation, although the dose-dependent response was much less
marked. As expected, the most significant effect was noted in
Fascia samples. In line with the DD results, low dose XiaflexH had
a greater effect than low dose Collagenase A, and Camptothecin
suppressed all cell lines (although interestingly to a lesser extent in
Fat).
The next stage of the RTCA experiments investigated whether
XiaflexH or Collagenase A had a sustained effect on DD or CT
fibroblasts following removal of the enzymes, assessing the cellular
recovery in the 24 hour period post-enzyme replacement with fresh
supWillE.BothDD and CTcelllines recovered fromthe suppressive
effects of both enzymes (although not to the same CI as pre-
treatment) and, to a lesser extent, from the cytotoxic Camptothecin.
InDDcells,Cordshowed a greater recoveryofgrowth thanNodule,
with some dose-dependent limitation of recovery in Nodule cells. In
CT, Skin and Fat recovered to a much greater extent than Fascia,
with no evidence of recovery being drug dose-dependent.
XiaflexH and Collagenase A Induce Membrane Leakage
and Reduce Cellular Viability/Metabolic activity in DD
Fibroblasts
The cytotoxic properties of XiaflexH and Collagenase A on DD
fibroblasts were assessed to corroborate the RTCA results and to
gain a more comprehensive understanding of the toxicity profiles
displayed by both enzymes. Analysis of cytotoxicity and cell
proliferation looked at both membrane disturbance and mito-
Figure 4. Effect of XiaflexH and Collagenase A on cell membrane integrity (cytotoxicity detection) and cell viability/metabolic
activity measured by LDH and WST-1 assays. A. LDH (lactose dehydrogenase) leakage assay for cell membrane integrity assessed the cytotoxic
effect of the drugs. B. WST-1 (water soluble-tetrazolium salt-1) assayed for cell viability/metabolic activity and cell death. *p,0.05, indicates
significant difference compared to untreated group. The data was expressed as average means 6 SEM from four independent experiments.
doi:10.1371/journal.pone.0031430.g004
XiaflexH Effect on DD Fibroblasts
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31430XiaflexH Effect on DD Fibroblasts
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31430chondrial activity. An LDH assay (Figure 4A) measured enzyme-
induced acute membrane disturbance and a WST-1 assay
(Figure 4B for DD and Supplementary Figure S7 for CT)
demonstrated the more long-term changes in cell viability/
metabolic activity (i.e. mitochondrial dehydrogenase activity).
The LDH results for the cytotoxicity of both enzymes show good
agreement with the RTCA results. XiaflexH, after 24 hours of
exposure, demonstrates a clear dose-dependent cytotoxic effect on
cultured fibroblasts from all anatomical sites. When compared
against Collagenase A, the lowest doses of XiaflexH appear to be
more potently cytotoxic than Collagenase A (although this is less
apparent than seen via RTCA). Results after a drug-free 24 hour
recovery period also demonstrated a primarily dose-dependent
cytotoxic response to XiaflexH with a reduced overall cytotoxicity
(in keeping with time-dependent increased cell growth and
illustrating the partial reversibility of the cytotoxic effect) but with
a greater degree of heterogeneity - Xia-400 ng showed a
comparatively greater cytotoxic response in DD-Skin, with
similarly enhanced responses to Xia-500 ng in DD-Nodule and
DD-Cord versus that seen with Xia-300 ng in DD-Fat. Collage-
nase A showed a reduced cytotoxicity (and hence reversibility of
effect) post drug removal across all the anatomical sites, although
there was a less-demonstrable dose-dependency. Finally, as
expected, the positive control Camptothecin showed strong
cytotoxicity at 24 hours of exposure across all anatomical sites,
with a minimal reduction in cytotoxic effect seen despite the
24 hour drug-free recovery period.
Moving to the WST-1 viability/metabolic activity assay results,
at 24 hours of exposure to XiaflexH, all DD cell types
demonstrated markedly reduced proliferation with minimal dose-
dependency. Collagenase A also caused reduced proliferation
across all DD cell types, with dose-dependent effects in DD-
Nodule but no dose-related effects in the other cell types. In DD-
Cord, Collagenase decreased proliferation more than XiaflexH,
whereas the opposite was true in DD-Fat. In CT samples, overall
both XiaflexH and Collagenase caused a reduction in proliferation,
however, in CT-Skin and CT-Fat there was a dose-dependent
reduction with XiaflexH whereas in CT-Fascia XiaflexH caused
reduced proliferation at low doses with a less marked effect at
higher doses.
Following the post-drug exposure recovery period, both DD
and CT samples showed some improvement in proliferation,
although not to pre-exposure levels. In all DD cell types there was
a dose-independent partial recovery of proliferation after all three
drugs. In the CT samples, all showed a return of proliferation but
only in CT-Fat this returned to near pre-drug levels (except after
XiaflexH low doses (300–400 ng) where there was a marked lack of
proliferative recovery).
XiaflexH Does not Induce Apoptosis in DD but may Cause
Direct Cell Death by Necrosis
It was hypothesised that XiaflexH and Collagenase A might
achieve their inhibitory effect on cell attachment, spreading and
proliferation via apoptosis or cellular necrosis and therefore this
hypothesis was assessed via dual-labelled FACS analysis (using
Annexin V and PI labelling). Annexin V detects early apoptosis
and propidium iodide (PI) identifies cell death. As is demonstrated
in Figure 5, XiaflexH showed no significant increase in Annexin V-
positive cells at 24 hours, whereas higher doses of Collagenase A
significantly (p,0.05) increased Annexin V-positive cells in DD
fibroblasts from all sites. PI-positive cells (indicating cellular
necrosis) were significantly (p,0.05) increased in both enzyme
groups in a dose-dependent manner (Figures 5A & 5B). Unlike in
DD fibroblasts, both enzymes significantly (p,0.05) increased the
Annexin V and PI positive cells in a dose-dependent manner in the
CT fibroblast groups (Supplementary Figure S8). From the above
results, it can be concluded that XiaflexH may cause necrosis but
not apoptosis in DD primary fibroblasts, while exposure of
primary DD fibroblasts to Collagenase A results in both necrosis
and apoptosis.
XiaflexH Downregulates the Expression of Collagen,
Fibronectin, a-SMA, TGF-b1 and MMP-9 at the
Transcriptional level in a Dose-Dependent manner
It has been shown previously that DD has been linked with
abnormal regulation of many ECM-associated genes, cytokines and
growth factors [55–69]. The impact of XiaflexH and Collagenase A
on the expression of some DD-associated fibrotic genes at the
mRNA level were therefore evaluated. Relative mRNA quantifica-
tion of a panel of pro-fibrotic genes in DD fibroblasts from all
locations revealed that XiaflexH (p,0.05) and/or Collagenase A
(p,0.01) significantly down-regulated the expression of collagens I
and III, fibronectin, alpha smooth muscle actin (a-SMA),
transforming growth factor beta one (TGF-b1) and matrix
metalloproteinase type-9 (MMP9) in a dose-dependent manner in
DD fibroblasts from one or more sites on day one. A similar trend
was also observed in primary fibroblasts isolated from CT samples
(Figure 6 and Supplementary Figure S9).
Treatment with both XiaflexH and Collagenase A resulted in
significant (p,0.05 or p,0.01), dose-dependent down-regulation
of both Collagen I and Collagen III as well as a-SMA in DD
fibroblasts isolated from all sites (Figures 6A, 6B and 6D) and from
primary CT fibroblasts from all sites (Supplementary Figures S9A,
S9B and S9C). The magnitude of the changes was generally
greater in cells treated with XiaflexH compared to cells treated
with Collagenase A.
Neither XiaflexH nor Collagenase A had any effect on the mRNA
expression levels of MMP2 in DD fibroblasts from any location
(Figure 6F) or from fibroblasts isolated from normal CT (Supple-
mentary Figure S9F). Likewise, neither XiaflexH nor Collagenase A
had any effect on MMP9 expression in fibroblasts isolated from the
DDcord. However,significant(p,0.05 or p,0.01) down-regulation
of MMP9 was detected in fibroblasts from DD nodule at the highest
doses of XiaflexH and Collagenase A (700 ng and 1000 ng,
respectively), in fibroblasts from DD fat at the higher dose of
Collagenase A and both doses of XiaflexH, and in normal skin at the
Figure 5. Detection of Early Apoptosis and Necrosis using Annexin V and PI. Fibroblasts from different anatomical sites (Nodule, Cord, Fat
and Skin) were treated with various concentration of XiaflexH and Collagenase A as indicated in the graphs. 24 hours post-treatment, cells were
harvested and labeled with Annexin V-FITC and PI. A. FITC-conjugated annexin V staining for untreated cells, upper left plot (labeled-untreated),
compared with the viable control cells, upper right plot (unlabeled cells). Dual-staining of treated cells (lower panel): the quadrant analysis shows
viable cells negative for annexin V and PI in the lower left, R3. Apoptotic cells stained with annexin V but excluding PI are shown in the lower right, R4.
Secondary necrotic cells (i.e. necrosis after apoptosis) positive for both PI and annexin V are shown in upper right, R2. Necrotic or mechanically
damaged cells positive for PI only are shown in upper left, R1. Representative data are shown from three independent experiments in triplicates.
B. Annexin V and PI positive cells after 24 hrs treatment with XiaflexH and Collagenase A at various concentrations as indicated in bar graph. Positive
cells were counted from three independent experiments and plotted on the graph as an average means 6 SEM. *p,0.05, indicates significant
difference compared to untreated group.
doi:10.1371/journal.pone.0031430.g005
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Collagenase A down-regulated MMP9 expression in fibroblasts
isolated from normal CT at all sites (Supplementary Figure S9G).
Neither XiaflexH norCollagenaseA had anyeffecton the expression
of NF-kb-p50 or NF-kb-p65 (RelA) in DD fibroblasts from any
location (Supplementary Figures S10A and S10B).
The effects of the two enzyme treatments on fibronectin and
TGF-b1 were not consistent in fibroblasts across all DD sites
(Figures 6C and 6E). Treatment of fibroblasts from all DD sites
with XiaflexH resulted in significant (p,0.05 or p,0.01) dose
dependent down-regulation of both fibronectin and TGF-b1; in
contrast, treatment with Collagenase A resulted in either no down-
regulation or down-regulation that was not dose dependent
(usually greater at the lower dose level). The exception was in
fibroblasts from DD Fat, where Collagenase A treatment resulted
in dose dependent down-regulation of TGF-b1. In normal CT,
however, both XiaflexH and Collagenase A resulted in significant
(p,0.05 or p,0.01), dose dependent down-regulation of both
genes (Supplementary Figures S9D and S9E).
Differential Expression of Collagen I and III and Effects of
XiaflexH or Collagenase A Treatment on Collagen
Expression in DD Primary Fibroblasts Isolated from
Different Anatomical Sites
Several groups have previously shown that collagen is over-
expressed in DD and the ratio of collagen I to III differs
[19,57,70], however variation in collagen expression between
fibroblasts isolated from different DD anatomical sites has not
previously been described. Hence, prior to studying the effect of
XiaflexH and Collagenase A on DD fibroblasts, the expression of
collagen I and III in DD fibroblasts isolated from different
anatomical sites was determined using capture sandwich and
indirect ELISA techniques respectively (Figure 7) [50,51].
Collagen expression patterns were significantly (p,0.05 or
p,0.01) different in DD fibroblasts from the different anatomical
sites when compared to those in DD skin fibroblasts. The highest
levels of both collagen I and III were detected in DD fibroblasts
isolated from Nodules, while fibroblasts from both DD Cord and
Fat had increased expression of both collagens relative to DD Skin
fibroblasts, but at lower relative levels than the Nodule fibroblasts.
In contrast to fibroblasts from DD Skin (where the level of collagen
I was greater than that of collagen III), collagen III levels were
higher than collagen I in DD fibroblasts from Nodule, Cord and
Fat. The protein expression results are generally consistent with
the mRNA expression patterns in fibroblasts from the same sites as
detected by qRT-PCR (Figures 6A and 6B).
Consistent with the result of the qRT-PCR analysis, treatment
of fibroblasts from all DD sites with either XiaflexH or Collagenase
A resulted in significant (p,0.05 or p,0.01), generally dose-
dependent reduction in collagen I and III expression (Figures 8 A
and B). Overall, the magnitude of reduction was greater in cells
treated with XiaflexH than in those treated with Collagenase A,
however no direct dose-to-dose comparison is possible due to the
inability to compare the defined activity of each enzyme and thus
the inability to normalise doses to enzyme activity.
XiaflexH Downregulates the Expression of Collagen,
Fibronectin, a-SMA, Desmin, Tenascin and CTGF at the
protein level in a Dose-Dependent Manner
DD is known to be associated with a number of molecular
abnormalities of cytokine and growth factor over-expression (e.g.
transforming growth factor beta (TGF-b), platelet derived growth
factor (PDGF) and connective tissue growth factor (CTGF))
[65,68,71,72] and over-expression of a number of ECM-associated
proteins (eg Collagen, Fibronectin, Tenascin and a-SMA). Hence, it
wasnecessarytocomparetheeffectofXiaflexHandCollagenaseAat
the molecular level on cytokines, growth factors and on the ECM-
associated proteins expressed by DD and CT fibroblasts isolated
from the different anatomical sites. For this purpose, we utilised a
novel, high throughput On-Cell and In-Cell Western blotting
technique [50,52–54]. In-Cell Western blotting results showed that
both drugs significantly (p,0.05) down-regulated a number of ECM
components and growth factor at the protein level, including
Collagen I, III and IV, Fibronectin, Tenascin, Desmin, a-SMA,
Figure 6. Measurement of comparative effect of Xiaflex and Collagenase A on mRNA steady-state levels of primary DD fibroblasts
isolated from different anatomical sites. A. Collagen I; B. Collagen III. #p,0.05 indicates significant difference in the expression of collagen I &
III in the Nodule compared to the Cord, Fat and Skin fibroblasts. +p,0.05 indicates significant difference in the expression of collagen I in Cord
compared to Fat and Skin fibroblasts. ++p,0.05 indicates significant difference in the expression of collagen I in Fat compared to Skin fibroblasts.
&p,0.05 indicates significant difference in the expression of collagen III in Cord compared to Skin fibroblasts. $p,0.05 indicates significant difference
in the expression of collagen III in Fat compared to Cord and Skin fibroblasts. C. Fibronectin; D. a-SMA; E. TGF-b I; F. MMP-2; G. MMP-9. *p,0.05,
**p#0.01 indicates significant difference between mRNA steady state levels of untreated and treated fibroblasts. The data presented here are the
averaged results from three independent experiments.
doi:10.1371/journal.pone.0031430.g006
Figure 7. In vitro quantitative measurement of collagen I and III
in DD fibroblasts. Synthesis of collagen I and III was measured by
capture sandwich ELISA (for collagen I expression) and Indirect ELISA
(for collagen III expression). *p,0.05, **p#0.01 indicates significant
difference compared to the DD-Skin fibroblasts. #p,0.05 indicates
significant difference in Nodule compared to the Cord, Fat and Skin
fibroblasts, in the expression of collagen I. ##p#0.01 indicates
significant difference in the expression of collagen III in Nodule
compared to Cord, Fat and Skin fibroblasts. The data presented here are
the means 6 SEM of three averaged independent experiments carried
out in triplicates.
doi:10.1371/journal.pone.0031430.g007
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DD fibroblasts from passages 1–4 were cultured in a 96 well plate (1.5610
4cells/well) andtreated with both drugs at various concentrations as indicated
in the figure. Cell lysates from treated and untreated cells were subjected to capture sandwich ELISA (for the detection of collagen I) and Indirect ELISA
(for the detection of collagen III) as described previously. A. Collagen I and B. Collagen III. *p,0.05, **p#0.01, indicate significant difference in treated
group compared to untreated control group. The data presented here are the average of three independent experiments performed in triplicates.
doi:10.1371/journal.pone.0031430.g008
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to be dose-dependent. However, as expected, the XiaflexH down-
regulatory effect on DD fibroblasts (pan-site) was evident at very low
concentrations compared to Collagenase A (Figures 9A–I). Surpris-
ingly, the effect of both drugs was significantly greater on the CT
fibroblast ECM proteins and cytokines (Supplementary Figures S11)
when compared with the noted effect on DD fibroblasts.
XiaflexH Induces Cell Cycle Marker Down-regulation and
Decreases Fibroblast proliferation
The results of the RTCA and WST-1 analyses indicated reduced
levels of cell attachment, spreading and proliferation and reduced
cell viability/metabolic activity in treated DD (Figures 3 and 4) and
CT (Supplementary Figures S6 and S7) fibroblasts. To further
investigate these findings, the expression of the cell cycle proteins
proliferating cell nuclear antigen (PCNA) and Cyclins D1 and 2 was
evaluated by qRT-PCR and In-Cell Western blotting to assess the
effects of XiaflexH and Collagenase A treatment on the cell cycle.
Significant (p,0.05 or p,0.01), dose-dependent down-regulation
of PCNA, Cyclin D1 and Cyclin D2 was detected in fibroblasts
treated with either XiaflexH or Collagenase A from all DD sites at
mRNA (Figure 10A) and protein level (Figure 10B) when compared
against the untreated control group of (pan-site) DD and CT
fibroblasts. However, as expected XiaflexH was able to achieve this
down-regulation at very low concentrations compared to Collage-
nase A in both DD and CT (Supplementary Figures S12).
XiaflexH Promotes DD Fibroblast Cellular Responses to
Injury and Wound Healing in vitro at Low Concentrations,
but Inhibits such Responses at Higher Concentrations
Several recent publications have reported that CCH enhances
the migration of keratinocytes and fibroblasts both in vitro and
promotes wound healing in vivo [73–75]. These effects have been
shown not to be directly attributable to the enzyme itself but instead
aremediatedby the in situ generationof collagenfragmentsfrom the
ECM and/or disruption of a2b1 integrin interactions with the ECM
[73–75]. In view of this, an in vitro wound model was utilised to look
at the response to injury via cell mobility - achievement of closure of
an artificially-created scratch wound was compared pre- and post-
exposure to XiaflexH and Collagenase A. The wound model
involved a fully (100%) confluent cell monolayer across which a
narrow scratch wound was created using a pipette tip. In the
presence of low concentrations of XiaflexH (300–400 ng) or
Collagenase A (250 ng), fibroblasts from all DD sites migrated into
the wound at a significantly (p,0.05) faster rate compared with the
site-matched untreated control group. However, at the higher
concentrations of either XiaflexH ($500 ng) or Collagenase A
($750 ng), the DD fibroblast migratory response to injury was
significantly (p#0.01) inhibited (Figures 11A and B).
Discussion
Dupuytren’s disease (DD) is a benign yet common fibroproli-
ferative disorder of the palmar fascia and represents an ideal
model to study tissue fibrosis. In addition, DD is a progressive,
irreversible and recurrent disabling disorder that significantly
impacts patients’ quality of life. Therefore, advancing knowledge
in how to effectively treat this clinically challenging disorder is of
paramount importance. The underlying cellular events involving
the abnormal synthesis of a number of ECM components (such as
collagen type I and III, a-smooth muscle actins, tenascin and
fibronectin) are important to our understanding of the complex
pathologic processes that result in the pathognomonic digital cord-
like contractures that significantly impair hand function.
CCHs are derived from Clostridium bacterial fermentation and
act to sequentially cleave collagen triple-helical molecules via
hydrolytic attack at the peptide bond of the tri-peptide subunit [28–
30], thus effecting enzymatic collagenolysis and cord rupture when
injected into DD fascial cords [31–35,44,76,77]. Collagenase A is a
comparatively basic CCH preparation designed for laboratory-
based tissue dissociation to liberate single cells for cellular culture
techniques. It comprises of clostridiopeptidase A, which uniquely
degrades the collagen triple-helical fibrils, coupled with clostripain
and a varietyofother proteases, whicheffectefficientdegradationof
the non-collagenous components of tissue ECM. Although a variety
of such collagenases have been commercially available for decades,
it was not until the advent of the novel CCH, XiaflexH, which has a
reproducible therapeutic in vivo effect based on its fixed ratio of
synergistic class I and II collagenases, that CCHs were clinically
utilised in the treatment of DD. Recent XiaflexH trials have
demonstrated correctionof DDfixed-flexiondeformities to near-full
digital extension (within#5u of extension) followingsingle- or multi-
dose CCH cord injections, with efficacy and safety profiles that
appear comparable in short- to mid-term follow-up to those of the
favoured surgical treatments [31–35].
This is the first published in vitro study demonstrating the effects
of XiaflexH on DD and CT primary fibroblasts obtained from
different anatomical sites. It is also the first study to compare such
effects against the long-standing commercially available Collage-
nase A. In this study, we used a variety of techniques (including
label-free RTCA, LDH, WST-1, FACS, qRT-PCR, ELISA, In-
cell Western Blotting and an in vitro scratch wound healing model)
and were able to assess the effects of XiaflexH compared to
Collagenase A on cultured DD and CT fibroblasts.
RTCA has not previously been utilised to assess DD fibroblast
growth - its great benefit is to dispense with complex labeling
procedures that may affect cellular behaviour and its ability to
monitor cell attachment, spreading and proliferation in real-time.
Thus, RTCA is able to assess the effect over time of applied drugs
and cellular recovery following drug removal. This mimics the
physiological behaviour of the cells more closely, giving greater
insight into possible in vivo responses. RTCA pilots demonstrated
that 10% FBS (added as a cell nutrient to the media) inhibited both
drugs’ action (at all concentrations); in view of this, the methodology
was modified, with use of FBS-free supWillE media for all later
experiments. The pilot demonstrated that XiaflexH exerts a greater
effect in supWillE than in supDMEM when comparing fibroblast
spreading, attachment and proliferation via RTCA. This discrep-
ancy is likely due to the presence of calcium and zinc in WillE as
Figure 9. Quantitative In-Cell Western blotting assay for the analysis of protein expression upon treatment with XiaflexH and
Collagenase A by DD fibroblasts. Primary fibroblasts were seeded in 96 well plate (1.5610
4cells/well) and allowed to grow for ,7–8 hours. The
cells were then treated with various concentrations of XiaflexH and Collagenase A as indicated. At 24 hours drug treatment, the cells were fixed in 4%
formaldehyde/PBS. In-Cell Western blotting was performed. Representative output infrared images of treated and untreated fibroblasts, stained for
protein expression (visible in green/red) from different anatomical sites are shown. Bar graphs represent the quantification of average protein
expression in different treatments from three independent experiments after normalization to loading control beta-actin. A. Collagen I; B. Collagen
III; C. Fibronectin; D. a-SMA; E. Desmin; F. Tenascin; G. Collagen IV; H. CTGF; I. MMP-9. *p,0.05, **p#0.01, indicate significant difference in treated
group compared to untreated control group. The data presented here are the means 6 SEM of triplicate experiments.unt: untreated.
doi:10.1371/journal.pone.0031430.g009
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cofactors to facilitate the enzymatic process [78] whereas DMEM
contains only calcium. It has been shown that calcium is essential to
maintain the appropriate structure of the collagen-binding site to
accept the triple-helical structure of the collagen fibrils but that Zinc
is required for overall activation of the catalytic site [78]. Obviously,
this is not an issue in in vivo XiaflexH application due to the supplied
buffer solution along with the local endogenous tissue presence of
the necessary metal cofactors.
Following the pilots, RTCA assessing the effect of untreated and
drug-treated DD fibroblast behaviour noted heterogeneity in the
untreated cellular behaviour depending on the anatomical deriva-
tion of the cells – fibroblasts isolated from Nodule and Cord were
abletogrowfasterand producehighercellnumbersthanthosefrom
Fat and Skin. This is not surprising when one reflects on the
pathological progression of this fibroproliferative disorder that
previously was thought to act as a benign tumour. Both Collagenase
A and XiaflexH effected inhibitionof DD cell spreading, attachment
and proliferationin a dose-and time-dependent manner.Thiseffect
was minimal at lower concentrations (50–100 ng doses), increasing
significantly with medium and high concentrations, and was fully
reversed (although without a return to the maximal cell indexes of
pre-drug exposure) within 24 hours of removal of either drug. This
could be of importance in understanding the mechanisms of disease
recurrence despite adequate initial collagenolysis.
To corroborate RTCA results and to compare the effect of both
drugs, we performed an end point membrane leakage (cytotoxicity
byLDH) assayanda cell viability/metabolicactivity(WST-1)assay.
LDH showed similar results when compared with those from
RTCA - LDH is a stable cytoplasmic enzyme stored in viable cells,
with any increase in its leakage indicating that the stability of cell
membranes is damaged. WST-1 showed both drugs inhibit pan-site
DD and CT cell viability/metabolic activity, with a reversal of the
inhibitory effect within 24 hours after removal of the drugs. These
results are in agreement with those of the previously discussed
RTCA. To get a comprehensive understanding of the inhibitory
effect of the drugs on cell proliferation, FACS was used to detect
early versus late apoptosis and necrosis after 24 hours of drug
treatment.UnlikeCollagenaseA,XiaflexHdoesnotcauseapoptosis,
but instead demonstrated dose-dependent pan-site DD direct cell
death via necrosis. In CT fibroblasts, both drugs showed early dose-
dependent apoptosis. Collagenase has been shown to cause
apoptosis in chondrocytes [79], and it has also been reported that
necrosis has been observed in in vitro models following treatment
with various Collagenases [80]. This study supports these previous
findings and could suggest a mechanism for disease recurrence post-
XiaflexH treatment due to the persistence of viable DD cells.
DD tissue has previously been noted to show up-regulation in
some ECM proteins, including cytokine and growth factors
[3,19,56,64,66,81] and with a notable alteration in the ratio of
collagens I to III. These results corroborate previously documented
over-expression of collagen in DD, plus demonstrate, for the first
time, heterogeneity in collagen type I and type III expression
patterns in primary fibroblasts isolated from different DD
anatomical sites. Nodule fibroblasts showed significantly higher
expression of collagen I and III at mRNA and protein levels as
compared to fibroblasts isolated from DD Cord, Fat and Skin. This
is in keeping with previous studies which describe the nodules as
being formed within the proliferative, most active pathological
phase within a disease noted for its over-expression of Collagen III
(compared to Collagen I) [2,82]. XiaflexH showed a dose-dependent
reduction in ECM transcription at the mRNA level in both DD and
CT pan-site fibroblasts, but with no significant effect on MMP-9
and nuclear transcription factor NF-kb. Unlike XiaflexH, Collage-
naseA treatmentresultedindown-regulationofallECMproteinsin
both DD and CT at the mRNA level. Comparatively, XiaflexH and
Collagenase A had a similar effect on the tested ECM components
and growth factors at an mRNA transcriptional level in both DD
and CT samples. Both drugs are composed of collagenolytic
enzymes and are primarily differentiated by their ratio of
constituent enzymes rather than having grossly different compo-
nents, so these results are unsurprising. However, it must be noted
there is a potential confounding factor in the use of this method to
assess collagens (which we intend to explore further in a future
study). The method assesses cell lysates and hence both the
intracellular collagen liberated on cell membrane disruption, plus
any collagen secreted by the cells prior to application of the tested
enzymes. This may mean that any enzyme-induced cellular death
(or apoptosis) resulting in cell loss could alter overall collagen release
due to cell lysis and that enzyme application could act on both cell
lysate-released collagen and previously secreted collagen, thus
complicating interpretation of the results.
To better understand the inhibitory effect exerted at the
molecular level by the drugs, cell-cycle regulated genes, PCNA,
Cyclin D1 and Cyclin D2 were analysed for mRNA and protein
expression. Both XiaflexH and Collagenase A down-regulated
these cell-cycle genes in a dose-dependent manner in both DD and
CT pan-site fibroblasts, with Collagenase A requiring much higher
concentrations to exert the same effect.
It has been shown previously that collagenase increases
keratinocyte and fibroblast cell migration and promotes both in
vitro and in vivo cellular responses at the wound area [73–75]. This
study demonstrates the effect of XiaflexH and Collagenase A on
the migration properties of DD and CT primary fibroblasts
isolated from different anatomical sites. Low concentrations of
both drugs were found to promote the cellular migration response
to repair a mechanically created wound, whereas, at higher
concentrations of the drugs this response was inhibited. This
supports the previously documented evidence that collagenases
can promote the cellular reparatory responses of injured skin –
examination of our data suggests that low amounts of collageno-
lysis may cause liberation of the cells from the ECM allowing
chemotactically drug-triggered migration into the damaged areas,
coupled with degradation of local collagen into smaller peptides
that may up-regulate cellular functions key to wound repair. This
is in comparison to the effect of higher concentrations at which the
collagenases appear to induce cellular necrosis by XiaflexH or
apoptosis by Collagenase A. This would infer that careful dosage
and administration of XiaflexH is very important: insufficient
concentrations or lack of infiltration of all diseased tissues might
increase the risk of recurrence. These findings are concerning
when one reflects there will always be lower concentrations around
Figure 10. Comparison of the effect of XiaflexH and Collagenase A on cell cycle regulation. Cell cycle gene (PCNA, Cyclin D1 and Cyclin
D2) were assessed at mRNA and protein levels using qRT-PCR and In-Cell Western blotting respectively. A. mRNA steady-state levels of cell cycle
genes (PCNA, Cyclin D1 and Cyclin D2) after treatment with XiaflexH and Collagenase A at various concentrations as indicated in the graphs. All the
cell cycle genes were dose-dependently down regulated by XiaflexH and Collagenase A compared to the untreated control group. B. Relative protein
expression of cell cycle proteins (PCNA and Cyclin D) after treatment with XiaflexH and Collagenase A. *p,0.05, **p#0.01, indicate significant
difference in treated group compared to untreated control group. The data presented here are the average of three independent experiments
performed in triplicate. Results are presented as means 6 SEM of triplicates.
doi:10.1371/journal.pone.0031430.g010
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response towards injury with and without drugs. Representative micrographs are shown from three independent experiments. B. Number of
migrated fibroblasts towards wound with and without drugs. Migrated cells into the wound area were counted based on the 0 hour migration
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on monocultured DD cell populations that are likely to act
differently from in vivo DD cells - to conclusively suggest increased
recurrence risk after exposure to lower doses of XiaflexH (and
hence the margins of all injection sites), further in vitro and ex vivo
organ culture model studies are required.
Throughout the experiments, XiaflexH was noted to achieve a
similar inhibitory effect on pan-site DD fibroblasts at significantly
lower concentrations when compared to Collagenase A, supporting
the manufacturer’s theory of greater potency due to the synergistic
effect of the contained set-ratio class I and II collagenases (AUX-I and
AUX-II). In addition, compared with other commercially-available
collagenase formulations, XiaflexH does not contain those previously
recognised impurities noted in other collagenase preparations e.g.
clostridial peptides, nonspecific proteases (e.g. caseinase) and other
bacterial production impurities that may impact cellular migration,
attachment and proliferation [24,36]. Interestingly, both drugs
showed a similar effect on the control CT fibroblasts - we are
currently unclear as to the precise mechanism of why XiaflexH
potency was not similar to that seen in DD cells. One explanation for
this discrepancy could be the reduced amount of collagen found in
the CT (i.e. normal fascia) samples which decreases the substrate
availability on which XiaflexH and Collagenase A can act.
DD cellular recovery following removal of both drugs was noted
in cells from all anatomical sites except DD fat. The precise
mechanism of this finding remains unclear and will require further
future investigation. However, the local cellular recovery (in all but
DD fat cells) does support the in vivo finding of the non-curative
nature of CCH-injection – the disease has been seen to recur
following XiaflexH injection [31].
This experimental study has demonstrated the effects at a cellular
and molecular level of the effects exerted by XiaflexH and
Collagenase A on DD and CT primary fibroblasts isolated from
different anatomical sites. These effects were primarily reversible on
removal of the drugs after 24 hours exposure, although this cannot
be directly compared with drug metabolism that occurs in vivo. The
observed cellularrecovery post-drug removal may also be dueto the
presence of myofibroblasts [56,60,62] and stem-like cells [45]
associated with DD that may lead to the recurrence of DD.
In conclusion, this is the first study to elucidate and compare the
mechanism of action of XiaflexH and Collagenase A at a cellular
and molecular level on DD and CT primary fibroblasts isolated
from different anatomical sites. Application of XiaflexH inhibits
cellular spreading, attachment and proliferation in a dose-
dependent and time-dependent manner at the cellular level and
also shows dose-dependent inhibition at the transcriptional level
for many ECM components, cytokine and growth factors.
Supporting Information
Figure S1 Schematic of Real-Time Cell Analyzer (RTCA)
with Microelectronic Sensory Array (MESA). (1) Loading
cells (1.5610
4cells/well) in supDMEM media. (2) Allowing cell
attachment and growth for 7–8 hours. (3) Adding the drugs at
various concentrations. (4) Monitoring the effect of drugs on cell
spreading, attachment and cell growth up to 24 hours. (5) Retrieval
of the drugs after 24 hours exposure. (6) Monitoring the reversibility
of inhibitory effect of drugs and cells were allowed to grow for
further 24 hours. (a) the cell index is 0 before loading the cells; (b)
the presence of cells affect the local ionic environment at the
electrode/solution interface, leading to increase in the electrode
impedance and cell index (CI); (c) when control cells (blue line)
continually proliferate and more cells attach to the electrodes,
leading to the large increase in electrode impedance, hence more
increase in CI; (d) when cells die off, shrink or decrease their surface
attachment (both intercellular and to the underlying electrode
surface) resulting from the exposure to a drug electrode impedance
decreases, hence CI decreases; (e) when the drug is retrieved, cells
will start spreading and growth will increases, hence electrode
impedance increases, leading to increase in CI.
(TIF)
Figure S2 Effect of XiaflexH and Collagenase A in the
presence of serum. A. Effect of XiaflexH and Collagenase A on
Dupuytren’s disease (DD)-Nodule fibroblasts. B. Effect of XiaflexH
and Collagenase A on DD-Cord fibroblasts.
(TIF)
Figure S3 Comparison of Effect of XiaflexH in DMEM
and WE supplemented media on Dupuytren’s disease
(DD) Nodule fibroblasts by Real-Time Cell Analyzer
(RTCA). DD-Nodule fibroblasts were seeded on 96-well E-plate
to a density of 1.5610
4cells/well and allowed to attach and grow
for 16–18 hours, following which XiaflexH diluted in supDMEM
and supWE was added at various concentrations as indicated in
graph. The cells were further monitored for 24 hours to assess and
compare the effect of XiaflexH in both media. The drug solutions
were removed after 24 hours and cells allowed to grow in drug-
free supDMEM and supWillE for a further 24 hours to assess the
reversibility of drug inhibition effect on cells.
(TIF)
Figure S4 Real-Time Cell Analyser (RTCA) Monitoring
of XiaflexH and Collagenase A effect on Dupuytren’s
disease (DD) primary fibroblasts from different ana-
tomical sites. A. Effect of XiaflexH and Collagenase A on DD-
Fat. B. Effect of XiaflexH and Collagenase A on DD-Skin.
(TIF)
Figure S5 Real-Time Cell Analyser (RTCA) Monitoring
ofXiaflexandCollagenase A effectonCarpalTunnel(CT)
primary fibroblasts from different anatomical sites.
Primary fibroblasts isolated from different anatomical sites of CT
(Fascia, Fat and Skin) were seeded onto 96-well E-plates
(1.5610
4cells/well) and cells grown for ,7–8 hours, prior to the
addition of XiaflexH or Collagenase A at various concentrations as
described in the methods section. After drug addition, cells were
allowed to grow for 24 hours in the presence of drugs. After
24 hours, the drugs were retrieved and the cells were fed with fresh
drug-free supWillE media, to assess the reversibility of the inhibitory
effect of both drugs over the following 24 hrs. Cell Indexes were
recorded every 15 mins. Each trace at each concentration was an
average of three replicates. A. Effect of XiaflexH and Collagenase A
on CT-Skin primary fibroblasts. B. Effect of XiaflexH and
Collagenase A on CT-Fat primary fibroblasts. C. Effect of XiaflexH
and Collagenase A on CT-Fascia primary fibroblasts. Representa-
tive data from six independent experiments in triplicates are shown.
(PPTX)
Figure S6 Real-Time Cell Analyser (RTCA) averaged
data of XiaflexH and Collagenase A effects on Carpal
Tunnel (CT) primary fibroblasts obtained from differ-
pattern from four micrographs for each treatment. Average of number of migrated cells, from three independent experiments carried out in triplicate
were plotted on the graph. *p,0.05, **p#0.01, indicate significant difference in the treated group compared to untreated control (WE+no_Drug)
group. #p,0.05 indicates significant difference compared to all the groups.
doi:10.1371/journal.pone.0031430.g011
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and treated groups from indicated time scale were taken from six
RTCA independent experiments and plotted on the graph.
(TIF)
Figure S7 Cell viability/metabolic activity measured by
WST-1 (water soluble-tetrazolium salt-1) assay after drug
treatment. CT-primary fibroblasts from different anatomical
sites (Fascia, Fat and Skin) were seeded in a 96-well plate at a
density of 1.5610
4cells/well. Cells were allowed to attach and
grow for ,7–8 hours prior to Xiaflex and Collagenase A addition
at various concentrations as indicated in the methods section. The
cells were grown for 24 hours in the presence of drugs. Following
24 hours, the drugs were removed and cells were supplemented
with drug-free supWillE media and reversibility of cell death and
cell proliferation was further assessed for 24 hours. WST-1 assay
for viability/metabolic activity. *p,0.05, indicates significant
difference compared to untreated group. The data are expressed
as a mean 6 SEM from three independent experiments.
(TIF)
Figure S8 Analysis of Annexin V and PI positive cells
after drug treatment. CT-primary fibroblasts were treated
with various concentration of XiaflexH and Collagenase A as
indicated in the graphs and subjected to Annexin V and PI
labeling. FITC-conjugated annexin V staining for untreated cells,
upper left plot (labeled-untreated), compared with the viable
control cells, upper right plot (unlabeled cells). Dual-staining of
treated cells (lower panel): the quadrant analysis shows: viable cells
negative for annexin V and excluding PI in lower left, R3;
Apoptotic cells stained with annexin V but excluding PI in lower
right, R4; Secondary necrotic cells (i.e. necrosis post-apoptosis),
positive for both PI and annexin V, shown in upper right, R2; and,
Necrotic or mechanically damaged cells positive for PI only shown
in the upper left, R1. Representative data are shown from three
independent experiments in triplicate.
(TIF)
Figure S9 Effect of Xiaflex and Collagenase A on mRNA
steady-state levels of primary CT fibroblasts. 24 hours
post-drug exposure at various concentrations as described in the
methods section, RNA was prepared and cDNA was synthesised
from 500 ng of RNA, following which qPCR was performed as
described previously. The effect of XiaflexH and Collagenase A on
mRNA transcription of: A. Collagen I; B. Collagen III; C. a-SMA;
D. Fibronectin; E. TGF-b I; F. MMP-2 and G. MMP-9. *p,0.05;
**p#0.01indicatessignificantdifferencebetweenmRNA expression
ofuntreated and treatedfibroblasts.Thedatapresented herearethe
average results from three independent experiments.
(PPTX)
Figure S10 Comparative effect of Xiaflex and Collage-
nase A on mRNA steady-state levels of primary Dupuyt-
ren’s disease (DD) fibroblasts isolated from different
anatomical sites. A. NF-kb-p50; B. NF-kb-Rela-p65. The data
presented here are the averaged results from three independent
experiments.
(TIF)
Figure S11 In-Cell Western blotting assay for the
analysis of protein expression. CT-primary fibroblasts were
seeded in 96-well plates (1.5610
4cells/well) and grown for ,7–
8 hours. Following which various concentrations of XiaflexH and
Collagenase A were added as described in the methods section.
24 hours post-drug treatment; the cells were fixed in 4%
formaldehyde/PBS. In-Cell Western blotting was performed as
described in the methods section. Representative output infrared
images of treated and untreated fibroblasts, stained for protein
expression (visible in green/red) are shown. Bar graphs represent
the quantification of average protein expression in different
treatments from three independent experiments. *p,0.05;
**p#0.01 indicates significant difference in the treated group
compared to the untreated control group. The data presented here
are the means 6SEM of triplicates. A. Collagen I; B. Collagen III;
C. Fibronectin; D. a-SMA; E. Collagen IV; F. Desmin; G.
Tenascin.
(PPTX)
Figure S12 Effect of XiaflexH and Collagenase A on cell
cycle regulation. Cell cycle genes (PCNA and Cyclin D1) were
assessed at mRNA and protein levels using qRT-PCR and In-Cell
Western blotting respectively as described in the methods section.
A. mRNA steady-state levels of PCNA. B. mRNA steady-state
levels of Cyclin D1, after 24 hours treatment. Both cell cycle genes
were dose-dependently down regulated by XiaflexH and Collage-
nase A compared to the untreated control group. C. Relative
protein expression of PCNA and, D. Relative protein expression
of Cyclin D, after 24 hours treatment. *p,0.05; **p#0.01
indicates significant difference in the treated group compared to
the untreated control group. The data presented here are the
average of three independent experiments performed in triplicate.
Results are presented as means 6 SEM of triplicates.
(PPTX)
Table S1 List of primers used for qRT-PCR.
(DOCX)
Table S2 List of primary antibodies utilised.
(DOCX)
Table S3 List of secondary antibodies utilised.
(DOCX)
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